...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Class prediction models of thrombocytosis using genetic biomarkers.
【24h】

Class prediction models of thrombocytosis using genetic biomarkers.

机译:使用遗传生物标记的血小板增多症的类别预测模型。

获取原文
获取原文并翻译 | 示例
           

摘要

Criteria for distinguishing among etiologies of thrombocytosis are limited in their capacity to delineate clonal (essential thrombocythemia [ET]) from nonclonal (reactive thrombocytosis [RT]) etiologies. We studied platelet transcript profiles of 126 subjects (48 controls, 38 RT, 40 ET [24 contained the JAK2V(617)F mutation]) to identify transcript subsets that segregated phenotypes. Cross-platform consistency was validated using quantitative real-time polymerase chain reaction (RT-PCR). Class prediction algorithms were developed to assign phenotypic class between the thrombocytosis cohorts, and by JAK2 genotype. Sex differences were rare in normal and ET cohorts (< 1% of genes) but were male-skewed for approximately 3% of RT genes. An 11-biomarker gene subset using the microarray data discriminated among the 3 cohorts with 86.3% accuracy, with 93.6% accuracy in 2-way class prediction (ET vs RT). Subsequent quantitative RT-PCR analysis established that these biomarkers were 87.1% accurate in prospective classification of a new cohort. A 4-biomarker gene subset predicted JAK2 wild-type ET in more than 85% patient samples using either microarray or RT-PCR profiling, with lower predictive capacity in JAK2V(617)F mutant ET patients. These results establish that distinct genetic biomarker subsets can predict thrombocytosis class using routine phlebotomy.
机译:区分血小板增多症病因的标准在区分克隆(基本血小板增多症[ET])和非克隆(反应性血小板增多症[RT])病因的能力方面受到限制。我们研究了126位受试者(48位对照,38位RT,40位ET [24位包含JAK2V(617)F突变])的血小板转录谱图谱,以鉴定分离表型的转录物子集。使用定量实时聚合酶链反应(RT-PCR)验证了跨平台一致性。开发了类别预测算法,以在血小板增多症队列之间并通过JAK2基因型分配表型类别。性别差异在正常人群和ET人群中很少见(不到基因的1%),但在大约3%的RT基因中却存在男性差异。使用微阵列数据的11个生物标志物基因子集在3个队列中进行了区分,准确度为86.3%,而双向分类(ET与RT)的准确度为93.6%。随后的定量RT-PCR分析确定,这些生物标志物在新队列的前瞻性分类中准确率为87.1%。 4-biomarker基因子集使用微阵列或RT-PCR分析法预测了超过85%的患者样本中的JAK2野生型ET,在JAK2V(617)F突变ET患者中的预测能力较低。这些结果表明,不同的遗传生物标志物亚群可以使用常规放血术预测血小板增多症的类别。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号